Cite
HARVARD Citation
Zaman, K. et al. (n.d.). Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. European journal of cancer. 51 (10), pp. 1212-1220. [Online].